keyword
MENU ▼
Read by QxMD icon Read
search

Dermatology treatment

keyword
https://www.readbyqxmd.com/read/29667795/psychopharmacology
#1
Sahil Sekhon, George Kroumpouzos, John Koo
Most dermatologists evaluate and treat patients with psychological or psychiatric issues related to their skin disease. These patients often require psychopharmacologic therapies. Therefore, it is important for dermatologists to be familiar about psychopharmacologic treatments for diseases that fit into the overlap between psychiatry and dermatology. This review aims to provide a concise overview of psychopharmacology as it applies to dermatology. Psychotropic medications commonly used in psychodermatology, including antidepressants, antipsychotics, and anxiolytics, are reviewed; safety profile and dosing recommendations are discussed...
April 18, 2018: Giornale Italiano di Dermatologia e Venereologia: Organo Ufficiale, Società Italiana di Dermatologia e Sifilografia
https://www.readbyqxmd.com/read/29667794/body-dysmorphic-disorder-in-the-cosmetic-practice
#2
Helena Kuhn, Paulo R Cunha, Natalie H Matthews, George Kroumpouzos
Body dysmorphic disorder (BDD) is a preoccupation with a slight or imagined flaw in appearance that causes significant distress and impairment in daily functioning. The disease is more prevalent among patients who seek aesthetic procedures as compared with population standards or individuals that are not interested in aesthetic surgery. Several studies have indicated that BDD symptoms typically worsen after an aesthetic procedure because the preoccupation shifts to a different body area. This article discusses the demographic and clinical features, psychiatric comorbidity, assessment, differential diagnosis, and management of BDD...
April 18, 2018: Giornale Italiano di Dermatologia e Venereologia: Organo Ufficiale, Società Italiana di Dermatologia e Sifilografia
https://www.readbyqxmd.com/read/29667792/habit-reversal-training-for-body-focused-repetitive-behaviors-a-practical-guide-for-the-dermatologist
#3
Amber B Dunbar, Michelle Magid, Jason S Reichenberg
Habit reversal training (HRT) is a clinically effective treatment for body-focused repetitive disorders (BFRDs) such as trichotillomania, onychophagia, and dermatillomania. Despite many dermatology providers knowing the term HRT, very few understand what HRT is and how it actually works. In this article, we give a detailed explanation of HRT and walk the reader through a six-session HRT protocol. We will briefly discuss adjunct interventions for BFRDs, including pharmacological approaches. We aim to make dermatologists more comfortable in offering basic HRT within their clinics and to close the gap that currently exists between patients who are HRT candidates and those who receive HRT treatment...
April 18, 2018: Giornale Italiano di Dermatologia e Venereologia: Organo Ufficiale, Società Italiana di Dermatologia e Sifilografia
https://www.readbyqxmd.com/read/29667728/comparison-of-10-efficient-protocols-for-photodynamic-therapy-of-actinic-keratosis-how-relevant-are-effective-light-dose-and-local-damage-in-predicting-the-complete-response-rate-at-3-months
#4
Anne-Sophie Vignion-Dewalle, Gregory Baert, Elise Thecua, Fabienne Lecomte, Claire Vicentini, Henry Abi-Rached, Laurent Mortier, Serge Mordon
BACKGROUND: Topical photodynamic therapy is an established treatment modality for various dermatological conditions, including actinic keratosis. In Europe, the approved protocols for photodynamic therapy of actinic keratosis involve irradiation with either an Aktilite CL 128 lamp or daylight, whereas irradiation with the Blu-U illuminator is approved in the United States. Many other protocols using irradiation by a variety of light sources are also clinically efficient. OBJECTIVES: This paper aims to compare 10 different protocols with clinically proven efficacy for photodynamic therapy of actinic keratosis and the available spectral irradiance of the light source...
April 18, 2018: Lasers in Surgery and Medicine
https://www.readbyqxmd.com/read/29665511/advanced-cutaneous-squamous-cell-carcinoma-a-retrospective-analysis-of-patient-profiles-and-treatment-patterns-results-of-a-non-interventional-study-of-the-decog
#5
Uwe Hillen, Ulrike Leiter, Sylvie Haase, Roland Kaufmann, Jürgen Becker, Ralf Gutzmer, Patrick Terheyden, Albrecht Krause-Bergmann, Hans-Joachim Schulze, Jessica Hassel, Nina Lahner, Uwe Wollina, Fabian Ziller, Jochen Utikal, Christine Hafner, Jens Ulrich, Hans-Günther Machens, Carsten Weishaupt, Axel Hauschild, Peter Mohr, Claudia Pföhler, Jan Maurer, Patrick Wolff, Christine Windemuth-Kieselbach, Dirk Schadendorf, Elisabeth Livingstone
BACKGROUND: Advanced cutaneous squamous cell carcinoma (aSCC) is an area of unmet medical need and no treatment standards are established. Recently, an anti-PD-1 inhibitor received FDA breakthrough therapy designation. The aim of the study was to describe the clinical course, therapeutic management and prognosis of aSCC under real-life conditions. PATIENTS AND METHODS: In a retrospective study performed in 24 German and Austrian hospitals and doctor's offices, patient and tumour characteristics of patients diagnosed with aSCC between January 1, 2010 and December 31, 2011 and their disease course was documented...
April 14, 2018: European Journal of Cancer
https://www.readbyqxmd.com/read/29664420/controlled-release-of-18-%C3%AE-glycyrrhetic-acid-by-nanodelivery-systems-increases-cytotoxicity-on-oral-carcinoma-cell-line
#6
Ilaria Cacciotti, Laura Chronopoulou, Cleofe Palocci, Adriana Amalfitano, Monica Cantiani, Massimo Cordaro, Carlo Lajolo, Cinzia Callà, Alma Boninsegna, Donatella Lucchetti, Patrizia Gallenzi, Alessandro Sgambato, Giuseppina Nocca, Alessandro Arcovito
The topical treatment for oral mucosal diseases is often based on products optimized for dermatologic applications; consequently, a lower therapeutic effect may be present.
 18-β-Glycyrrhetic Acid (GA) is extracted from Glycirrhiza glabra. The first aim of this study was to test the cytotoxicity of GA on PE/CA-PJ15 cells. The second aim was to propose and test two different delivery systems, i.e. nanoparticles and fibers, to guarantee a controlled release of GA in vitro. We used chitosan and poly(lactic-co-glycolic) acid based nanoparticles and polylactic acid fibers...
April 17, 2018: Nanotechnology
https://www.readbyqxmd.com/read/29663335/long-term-efficacy-of-add-on-lacosamide-treatment-in-children-and-adolescents-with-refractory-epilepsies-a-single-center-observational-study
#7
Anna Rosati, Lucrezia Ilvento, Riccardo Rizzi, Viola Doccini, Maria Carmela Leo, Alessandra Pugi, Salvatore De Masi, Renzo Guerrini
OBJECTIVE: To assess long-term efficacy and tolerability of lacosamide (LCM) as adjunctive treatment through a retrospective study in children and adolescents with refractory epilepsies. METHODS: All patients consecutively treated with LCM as add-on for refractory focal and generalized epilepsy and followed at the Neuroscience Center of Excellence of the Meyer Children's Hospital of Florence between January 2011 and September 2015 were included in the study. Responder rate, relapse-free survival, and retention rate were calculated...
April 17, 2018: Epilepsia
https://www.readbyqxmd.com/read/29653208/efficacy-and-safety-of-ixekizumab-over-4-years-of-open-label-treatment-in-a-phase-2-study-in-chronic-plaque-psoriasis
#8
Claus Zachariae, Kenneth Gordon, Alexandra Kimball, Mark Lebwohl, Andrew Blauvelt, Craig Leonardi, Daniel Braun, Missy McKean-Matthews, Russel Burge, Gregory Cameron
BACKGROUND: Ixekizumab has demonstrated improvement in moderate-to-severe psoriasis patients by selectively targeting interleukin-17A, a pro-inflammatory cytokine important in psoriasis pathogenesis. OBJECTIVE: To report 4-year efficacy and safety results from the open-label extension (OLE) of this phase 2 trial. METHODS: Analysis was by last observation carried forward. Patients received ixekizumab 120 mg then 80 mg subcutaneously once every 4 weeks...
April 10, 2018: Journal of the American Academy of Dermatology
https://www.readbyqxmd.com/read/29651917/erythematous-skin-lesions-with-necrotic-centers-on-lower-extremities-due-to-the-use-of-ruxolitinib-for-primary-myelofibrosis
#9
Constantin A Dasanu
Ruxolitinib is a small molecule JAK-2 inhibitor approved for the treatment of certain myeloproliferative neoplasms. Ruxolitinib-related skin toxicity is extremely rare. We report herein an unusual erythematous skin eruption with necrotic centers involving lower extremities in a patient with primary myelofibrosis treated with ruxolitinib. Awareness of this unusual skin toxicity with ruxolitinib becomes even more important as JAK-2 inhibition might soon find clinical applications in dermatology.
January 1, 2018: Journal of Oncology Pharmacy Practice
https://www.readbyqxmd.com/read/29651516/-skin-cancer-screening-and-treatment-costs-utilisation-of-the-skin-cancer-screening-and-skin-cancer-treatment-costs-in-organ-transplant-recipients
#10
D Jäckel, N I Schlothauer, H Zeeb, G Wagner, M M Sachse
BACKGROUND: Organ transplant recipients have an up to 250-times higher risk to develop skin cancer. This article evaluated the utilisation of skin cancer screening and the treatment costs for skin cancer in organ transplant recipients. Patients of the health insurance AOK Bremen/Bremerhaven had been identified and the need for skin cancer prevention trainings was derived. METHODS: The number of organ transplant recipients (ICD code Z94.0-4) with and without any history of skin cancer (ICD code C43/C44), the utilisation of dermatologic health care services, and the costs for treatments with the diagnosis Z94...
April 12, 2018: Der Hautarzt; Zeitschrift Für Dermatologie, Venerologie, und Verwandte Gebiete
https://www.readbyqxmd.com/read/29650685/osimertinib-a-novel-dermatologic-adverse-event-profile-in-patients-with-lung-cancer
#11
Chia-Yu Chu, Jennifer Choi, Beth Eaby-Sandy, Corey J Langer, Mario E Lacouture
Dermatologic adverse events (dAEs) are common with the use of epidermal growth factor receptor-tyrosine kinase inhibitor (EGFR-TKI) therapy. First- and second-generation agents (erlotinib, gefitinib, and afatinib) are frequently associated with acneiform rash, pruritus, xerosis, and paronychia; the incidence and characterization of these dAEs have been well described. However, there is evidence that the dAE profile is different with third-generation EGFR-TKIs. Herein, we describe the dAEs associated with third-generation EGFR-TKIs and our clinical experience with osimertinib, a third-generation EGFR-TKI approved by the U...
April 12, 2018: Oncologist
https://www.readbyqxmd.com/read/29648825/rational-drug-design-of-topically-administered-caspase-1-inhibitors-for-the-treatment-of-inflammatory-acne
#12
Jean-Francois Fournier, Laurence Clary, Sandrine Chambon, Laurence Dumais, Craig Steven Harris, Corinne Millois-Barbuis, Romain Pierre, Sandrine Talano, Etienne Thoreau, Jérome Aubert, Michèle Aurelly, Claire Bouix-Peter, Anne Brethon, Laurent Chantalat, Olivier Christin, Catherine Comino, Ghizlane El-Bazbouz, Anne-Laurence Ghilini, Tatiana Isabet, Claude Lardy, Anne-Pascale Luzy, Céline Mathieu, Kenny Mebrouk, Danielle Orfila, Jonathan Pascau, Kevin Reverse, Didier Roche, Vincent Rodeschini, Laurent François Hennequin
The use of an interleukin beta antibody is currently being investigated in the clinic for the treatment of acne, a dermatological disorder affecting 650M persons globally. Inhibiting the protease responsible for the cleavage of inactive pro-IL1β into active IL-1β, caspase-1, could be an alternative small molecule approach. This report describes the discovery of uracil 20, a potent (38 nM in THP1 cells assay) caspase-1 inhibitor for the topical treatment of inflammatory acne. The uracil series was designed according to published caspase-1 pharmacophore model involving a reactive warhead in P1 for covalent reversible inhibition and an aryl moiety in P4 for selectivity against the apoptotic caspases...
April 12, 2018: Journal of Medicinal Chemistry
https://www.readbyqxmd.com/read/29645394/cicatricial-alopecia
#13
Varvara Kanti, Joachim Röwert-Huber, Annika Vogt, Ulrike Blume-Peytavi
In the classification of the North American Hair Research Society, primary cicatricial alopecias (PCA) are divided into four groups according to their prominent inflammatory infiltrate: PCAs with lymphocytic, neutrophilic, mixed or nonspecific cell inflammation pattern. The hair loss can begin subclinically and progress slowly so that the exact onset of the disease is often difficult to determine. The diagnosis is often delayed. While most forms of cicatricial alopecia can be clearly diagnosed based on clinical presentation in the acute disease stage, diagnosis can be challenging in the subacute, early or late disease stages...
April 2018: Journal der Deutschen Dermatologischen Gesellschaft, Journal of the German Society of Dermatology: JDDG
https://www.readbyqxmd.com/read/29645380/s1-guidelines-dermatoses-associated-with-dermal-lymphostasis
#14
Joachim Dissemond, Finja Jockenhöfer, Anya Miller, Günter Kurzhals, Shahrouz Noori, Stefanie Reich-Schupke, Martin Schlaeger, Erich Schubert, Markus Stücker, Tobias Weberschock, Hans Wilfried Jungkunz
The objective of the present S1 guidelines is to present current knowledge about dermatologically relevant diseases associated with localized dermal lymphostasis, thus facilitating their early detection, diagnostic workup, and targeted treatment. Whenever possible, treatment should be based on stage-appropriate and clearly defined algorithms. The numerous issues regarding differential diagnosis and treatment clinicians are confronted with in everyday clinical practice seem to warrant the publication of up-to-date guidelines...
April 2018: Journal der Deutschen Dermatologischen Gesellschaft, Journal of the German Society of Dermatology: JDDG
https://www.readbyqxmd.com/read/29630148/representation-and-treatment-allocation-of-racial-groups-in-dermatologic-therapy-trials-a-2-year-review-of-the-literature
#15
Christina K Park, Raed Alhusayen
Although most investigators would agree that including minority races in clinical trials is important, recruitment and retention may differ among these populations. The objective of this review was to perform an audit of phase III dermatologic therapy trials to determine representation for minority groups and to explore the possibility of racial allocation bias. In this review of 11 dermatology or general medicine journals in 2015-16, we did not find evidence of systemic racial allocation bias. We did however note variation in the proportion of minority races included in studies; whereas some trials had high success in recruiting minorities, many did not...
February 15, 2018: Dermatology Online Journal
https://www.readbyqxmd.com/read/29626322/a-scoping-review-protocol-to-explore-the-use-of-interleukin-1-targeting-drugs-for-the-treatment-of-dermatological-diseases-indications-mechanism-of-action-efficacy-and-safety
#16
REVIEW
Francisco Gómez-García, Juan Ruano, Jesús Gay-Mimbrera, Macarena Aguilar-Luque, Juan L Sanz-Cabanillas, José L Hernández Romero, Antonio Velez Garcia-Nieto
INTRODUCTION: The interleukin (IL)-1 pathway has been identified as being involved in inflammatory and neoplastic skin diseases such as psoriasis, atopic dermatitis, neutrophilic dermatosis, melanoma, and squamous cell carcinoma. Drugs developed to target the IL-1 pathway are currently used to treat these pathologies, and although they are becoming more selective, they are not exempt from adverse events and high costs. Integrating the best research evidence with clinical experience and patient needs has been shown to improve care, health, and cost outcomes...
April 6, 2018: Dermatology and Therapy
https://www.readbyqxmd.com/read/29625968/2018-update-of-the-eular-recommendations-for-the-management-of-beh%C3%A3-et-s-syndrome
#17
Gulen Hatemi, Robin Christensen, Dongsik Bang, Bahram Bodaghi, Aykut Ferhat Celik, Farida Fortune, Julien Gaudric, Ahmet Gul, Ina Kötter, Pietro Leccese, Alfred Mahr, Robert Moots, Yesim Ozguler, Jutta Richter, David Saadoun, Carlo Salvarani, Francesco Scuderi, Petros P Sfikakis, Aksel Siva, Miles Stanford, Ilknur Tugal-Tutkun, Richard West, Sebahattin Yurdakul, Ignazio Olivieri, Hasan Yazici
Several new treatment modalities with different mechanisms of action have been studied in patients with Behçet's syndrome (BS). The aim of the current effort was to update the recommendations in the light of these new data under the auspices of the European League Against Rheumatism (EULAR) Standing Committee for Clinical Affairs. A task force was formed that included BS experts from different specialties including internal medicine, rheumatology, ophthalmology, dermatology, neurology, gastroenterology, oral health medicine and vascular surgery, along with a methodologist, a health professional, two patients and two fellows in charge of the systematic literature search...
April 6, 2018: Annals of the Rheumatic Diseases
https://www.readbyqxmd.com/read/29623021/biochemical-aspects-of-mammalian-melanocytes-and-the-emerging-role-of-melanocyte-stem-cells-in-dermatological-therapies
#18
REVIEW
Sharique A Ali, Ishrat Naaz
Skin color in animals is richer than human beings and is determined by different types of pigments. Melanin is the key pigment responsible for the diverse pigmentation found in animal and human skin, hair, and eyes. Melanin pigment is synthesized by melanocytes and is consecutively transferred to adjacent keratinocytes; here, it acts as an internal sunscreen to defend from ultraviolet (UV) damage. Any defect in the process of melanocytes development and/or melanin synthesis results in esthetic problem of abnormal pigmentation...
January 2018: International Journal of Health Sciences
https://www.readbyqxmd.com/read/29619987/comorbidities-of-bullous-pemphigoid-in-a-finnish-cohort
#19
Anna Pankakoski, Harri Sintonen, Annamari Ranki, Nicolas Kluger
The incidence of bullous pemphigoid (BP) is increasing in Finland. To investigate the clinical presentation, comorbidities, and medications in a cohort of Finnish patients with confirmed BP managed in a university hospital setting. An observational retrospective study of all consecutive patients diagnosed with BP in 2012-2013 at the Department of dermatology, HUCH. The prevalence of the most common comorbidities was compared to that in a sample population aged over 30 years. Seventy patients were included (mean age: 77 years at diagnosis)...
April 5, 2018: European Journal of Dermatology: EJD
https://www.readbyqxmd.com/read/29614495/commentary-on-the-evidence-and-consensus-based-s3-guidelines-for-the-treatment-of-actinic-keratosis-published-by-the-international-league-of-dermatological-societies-in-cooperation-with-the-european-dermatology-forum
#20
Thomas L Diepgen, Joachim Kresken, Jean Krutmann, Hans F Merk, Erik Senger, Christian Surber, Rolf-Markus Szeimies
In 2015, the International League of Dermatological Societies and the European Dermatology Forum published a guideline for the treatment of actinic keratosis, which is classified as an evidence- and consensus-based S3 guideline. From the point of view of the GD Task Force "Licht.Hautkrebs.Prävention," an interdisciplinary expert panel of the Society for Dermopharmacy for the prevention and treatment of skin cancer, this guideline reveals strengths and weaknesses but, in summary, does not meet the claim for an evidence- and consensus-based S3 guideline...
April 3, 2018: Skin Pharmacology and Physiology
keyword
keyword
81333
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"